Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Collaboration › Details

BioNTech–Akampion: public relations, 201709 service existent by Akampion

 

Period Period 2017-09-19
Organisations Partner, 1st BioNTech AG
  Group BioNTech (Group)
  Partner, 2nd Akampion
Products Product public relations / investor relations / marcom (services)
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person Weß, Ludger (akampion before 2001–2006 BioCentury Senior Editor before Financial Times Deutschland)
  Person 2 Buth, Ines-Regina (akampion 200901 before Micromet Head Investor Relations before Lion Bioscience)
     

BioNTech AG. (9/19/17). "Press Release: BioNTech AG to Present at Cantor Fitzgerald Healthcare Conference". Mainz.

BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at the Cantor Fitzgerald Healthcare Conference that is being held in New York, NY from September 25-27, 2017. The presentation is scheduled for Tuesday, September 26 at 2:50 PM Eastern Daylight Time.

Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations and a summary of its most recent Nature publication related to its neo-epitope based individualized mRNA cancer immunotherapeutic.


For more information, please contact:

General Inquiries:

BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273
Email: Regina.Jehle@biontech.de

US Media & Investors:
ICR Healthcare
James Heins / Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282
Email: James.Heins@icrinc.com
Email: Stephanie.Carrington@icrinc.com

International Media & Investor Inquiries:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768
Email: info@akampion.com


About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for treatment of cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel bispecific antibody- based immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s financial shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at www.biontech.de.

   
Record changed: 2018-07-16

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for BioNTech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top